Evidence map›Paper›PMID 34359597›Full record

ReviewCancers2021

Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies.

Luigi Lorini, Coro Bescós Atín, Selvam Thavaraj, Urs Müller-Richter, Margarita Alberola Ferranti, Jorge Pamias Romero, Manel Sáez Barba, Alba de Pablo García-Cuenca, Irene Braña García, Paolo Bossi and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The dual role of diabetes on oral potentially malignant disorders.European journal of medical research · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Luigi LoriniMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, 25123 Brescia, Italy.
Coro Bescós AtínOral and Maxillofacial Department, Vall d'Hebron University Hospital, 08035 Barcelons, Spain.
Selvam ThavarajHead and Neck Pathology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RS, UK.ORCID 0000-0001-5720-7422
Urs Müller-RichterComprehensive Cancer Center and Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, 97070 Würzburg, Germany and Bavarian Centre for Cancer Research, 97070 Würzburg, Germany.ORCID 0000-0001-7869-7686
Margarita Alberola FerrantiDepartment of Pathology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Jorge Pamias RomeroOral and Maxillofacial Department, Vall d'Hebron University Hospital, 08035 Barcelons, Spain.
Manel Sáez BarbaOral and Maxillofacial Department, Vall d'Hebron University Hospital, 08035 Barcelons, Spain.
Alba de Pablo García-CuencaOral and Maxillofacial Department, Vall d'Hebron University Hospital, 08035 Barcelons, Spain.
Irene Braña GarcíaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Paolo BossiMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-0135-0224
Paolo NuciforoMolecular Oncology Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Sara SimonettiMolecular Oncology Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.ORCID 0000-0003-2406-030X
Vall d'Hebron Hospital Universitari · ESUniversity of Brescia · ITVall d'Hebron Institute of Oncology · ESComprehensive Cancer Center Mainfranken · DEGuy's and St Thomas' NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC) is a very aggressive cancer, representing one of the most common malignancies worldwide. Oral potentially malignant disorders (OPMDs) regroup a variegate set of different histological lesions, characterized by the potential capacity to transform in OSCC. Most of the risk factors associated with OSCC are present also in OPMDs' development; however, the molecular mechanisms and steps of malignant transformation are still unknown. Treatment of OSCC, including surgery, systemic therapy and radiotherapy (alone or in combination), has suffered a dramatic change in last years, especially with the introduction of immunotherapy. However, most cases are diagnosed during the advanced stage of the disease, decreasing drastically the survival rate of the patients. Hence, early diagnosis of premalignant conditions (OPMDs) is a priority in oral cancer, as well as a massive education about risk factors, the understanding of mechanisms involved in malignant progression and the development of specific and more efficient therapies. The aim of this article is to review epidemiological, clinical, morphological and molecular features of OPMDs, with the purpose to lay the foundation for an exhaustive comprehension of these lesions and their ability of malignant transformation and for the development of more effective and personalized treatments.

Indexed as

molecular alterationsmorphological featuresoral potentially malignant disordersrisk factors and etiologytreatment

Identifiers

PMID34359597
PMCPMC8345150
OpenAlexW3185369173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.